{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:11Z","timestamp":1791499991623,"version":"4.3.4"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022809","name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109124","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:51:35Z","timestamp":1789253495000},"page":"109124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neuroregulation as a modulatory force in immune checkpoint inhibitor resistance: mechanistic neuro-immune crosstalk informing biomarker-led diagnosis and targetable therapeutic sensitization"],"prefix":"10.1016","volume":"288","author":[{"given":"Mingze","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyu","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109124_bb0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12974-021-02368-9","article-title":"Social isolation induces neuroinflammation and microglia overactivation, while dihydromyricetin prevents and improves them","volume":"19","author":"Al Omran","year":"2022","journal-title":"Journal of Neuroinflammation"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109124_bb0010","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.3390\/cancers14194817","article-title":"Nerve density and neuronal biomarkers in cancer","volume":"14","author":"Ali","year":"2022","journal-title":"Cancers"},{"issue":"7644","key":"10.1016\/j.pharmthera.2026.109124_bb0015","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nature21508","article-title":"Immunology: The chronicles of T-cell exhaustion","volume":"543","author":"Amezquita","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0020","article-title":"Neuro-immune cross-talk in cancer. Nature reviews","author":"Amit","year":"2025","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrc.2016.38","article-title":"Mechanisms of cancer dissemination along nerves","volume":"16","author":"Amit","year":"2016","journal-title":"Nature Reviews Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"28","key":"10.1016\/j.pharmthera.2026.109124_bb0035","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109124_bb0040","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109124_bb0045","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","article-title":"Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells","volume":"175","author":"Baratelli","year":"2005","journal-title":"Journal of Immunology"},{"issue":"8084","key":"10.1016\/j.pharmthera.2026.109124_bb0050","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-025-09370-8","article-title":"Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy","volume":"646","author":"Baruch","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treatment Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0065","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41417-023-00599-x","article-title":"\u03923-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-\u03b3-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma","volume":"30","author":"Bruno","year":"2023","journal-title":"Cancer Gene Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109124_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Science Advances"},{"issue":"7637","key":"10.1016\/j.pharmthera.2026.109124_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0080","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.cmet.2023.07.009","article-title":"NSUN2 is a glucose sensor suppressing cGAS\/STING to maintain tumorigenesis and immunotherapy resistance","volume":"35","author":"Chen","year":"2023","journal-title":"Cell Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2026.2652476","article-title":"Modulating the gut microbiota to enhance immune checkpoint inhibitor efficacy in colorectal cancer: Mechanisms, therapeutic strategies, and clinical perspectives","volume":"18","author":"Chen","year":"2026","journal-title":"Gut Microbes"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0090","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.crimmu.2021.11.001","article-title":"Role of adrenergic receptor signalling in neuroimmune communication","volume":"2","author":"Chhatar","year":"2021","journal-title":"Current Research in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109124_bb0095","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","article-title":"Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy","volume":"25","author":"Chowell","year":"2019","journal-title":"Nature Medicine"},{"issue":"6375","key":"10.1016\/j.pharmthera.2026.109124_bb0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"issue":"34","key":"10.1016\/j.pharmthera.2026.109124_bb0105","doi-asserted-by":"crossref","first-page":"55804","DOI":"10.18632\/oncotarget.18437","article-title":"Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells","volume":"8","author":"Clavijo","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109124_bb0110","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6529","key":"10.1016\/j.pharmthera.2026.109124_bb0115","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0120","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI82658","article-title":"Schwann cells induce cancer cell dispersion and invasion","volume":"126","author":"Deborde","year":"2016","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0125","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.immuni.2025.12.016","article-title":"Tumor-associated macrophages enhance peripheral nerve tumor infiltration and spinal cord repair","volume":"59","author":"Dolci","year":"2026","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0130","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf082","article-title":"Unveiling a novel cancer hallmark by evaluation of neural infiltration in cancer","volume":"26","author":"Dong","year":"2025","journal-title":"Briefings in Bioinformatics"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0135","first-page":"345","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews","volume":"18","author":"Doroshow","year":"2021","journal-title":"Clinical Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109124_bb0140","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0145","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s41418-023-01209-x","article-title":"Netrin-1 blockade inhibits tumor associated myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor","volume":"30","author":"Ducarouge","year":"2023","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: Why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65048-9","article-title":"\u03b2-Adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells","volume":"16","author":"Fj\u00e6stad","year":"2025","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/1078-0432.CCR-20-2381","article-title":"Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: Safety, tolerability, and preliminary evidence of antitumor activity","volume":"27","author":"Gandhi","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0165","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220610","article-title":"Pleiotrophin drives a prometastatic immune niche in breast cancer","volume":"220","author":"Ganguly","year":"2023","journal-title":"Journal of Experimental Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0170","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0896-6273(00)80778-3","article-title":"Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons","volume":"23","author":"Gleeson","year":"1999","journal-title":"Neuron"},{"issue":"7982","key":"10.1016\/j.pharmthera.2026.109124_bb0180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","article-title":"The \u03b21-adrenergic receptor links sympathetic nerves to T cell exhaustion","volume":"622","author":"Globig","year":"2023","journal-title":"Nature"},{"issue":"6371","key":"10.1016\/j.pharmthera.2026.109124_bb0185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109124_bb0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7150\/jca.17144","article-title":"Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor","volume":"8","author":"Guo","year":"2017","journal-title":"Journal of Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: New insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109124_bb0200","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147276","article-title":"Tumor innervation: Peripheral nerves take control of the tumor microenvironment","volume":"131","author":"Gysler","year":"2021","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109124_bb0205","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109124_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202105118","article-title":"Multifunctional immunoliposomes enhance the immunotherapeutic effects of PD-L1 antibodies against melanoma by reprogramming immunosuppressive tumor microenvironment","volume":"18","author":"Hei","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","article-title":"Spatial multi-omics analyses of the tumor immune microenvironment","volume":"29","author":"Hsieh","year":"2022","journal-title":"Journal of Biomedical Science"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109124_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000172","article-title":"Nerve fibers in breast cancer tissues indicate aggressive tumor progression","volume":"93","author":"Huang","year":"2014","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0235","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41556-021-00820-9","article-title":"Cancer cell-derived GABA promotes \u03b2-catenin-mediated tumor growth and immunosuppression","volume":"24","author":"Huang","year":"2022","journal-title":"Nature Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0240","article-title":"Targeting MDSC-HTR2B to improve immune checkpoint inhibitors in breast to brain metastasis","author":"Iyer","year":"2024","journal-title":"Biorxiv"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0245","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3390\/biomedicines12102335","article-title":"Remarks on selected morphological aspects of cancer neuroscience: A microscopic photo review","volume":"12","author":"I\u017cycka-\u015awieszewska","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0250","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"British Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2016.09.003","article-title":"T-cell immunometabolism against cancer","volume":"382","author":"Jiang","year":"2016","journal-title":"Cancer Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0260","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","article-title":"Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer","volume":"31","author":"Jiang","year":"2023","journal-title":"Cell Host & Microbe"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0265","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/cbdd.13677","article-title":"Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy","volume":"95","author":"Kalim","year":"2020","journal-title":"Chemical Biology & Drug Design"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0270","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"Journal of Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109124_bb0275","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2326-6066.CIR-22-0815","article-title":"High expression of MHC class I overcomes cancer immunotherapy resistance due to IFN\u03b3 signaling pathway defects","volume":"11","author":"Kawase","year":"2023","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2022.01.017","article-title":"Prognostic and predictive value of \u03b2-blockers in the EORTC 1325\/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","volume":"165","author":"Kennedy","year":"2022","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0285","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41598-023-28073-6","article-title":"Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice","volume":"13","author":"Kittikulsuth","year":"2023","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109124_bb0290","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1405205","article-title":"Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice","volume":"7","author":"Kokolus","year":"2017","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: A study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","journal-title":"ESMO Open"},{"issue":"6349","key":"10.1016\/j.pharmthera.2026.109124_bb0300","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"5256","key":"10.1016\/j.pharmthera.2026.109124_bb0305","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.617658","article-title":"T cells plead for rejuvenation and amplification; with the brain\u2019s neurotransmitters and neuropeptides we can make it happen","volume":"12","author":"Levite","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2021.102159","article-title":"Neurotransmitters and neuropeptides decrease PD-1 in T cells of healthy subjects and patients with hepatocellular carcinoma (HCC), and increase their proliferation and eradication of HCC cells","volume":"89","author":"Levite","year":"2021","journal-title":"Neuropeptides"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0320","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li","year":"2020","journal-title":"Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101212","article-title":"Sciatic nerve stimulation enhances NK cell cytotoxicity through dopamine signaling and synergizes immunotherapy in triple-negative breast cancer","volume":"79","author":"Li","year":"2025","journal-title":"Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0330","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3892\/mmr.2015.3374","article-title":"Vasoactive intestinal peptide induces CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells in gastric cancer","volume":"12","author":"Li","year":"2015","journal-title":"Molecular Medicine Reports"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109124_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401061","article-title":"Pan-cancer single-cell and spatial-resolved profiling reveals the immunosuppressive role of APOE+ macrophages in immune checkpoint inhibitor therapy","volume":"11","author":"Liu","year":"2024","journal-title":"Advanced Science"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0340","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1038\/s41467-021-25967-9","article-title":"Environmental eustress modulates \u03b2-ARs\/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1496627","article-title":"A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: Current status, and the application of advanced imaging approaches and artificial intelligence","volume":"15","author":"Liu","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109124_bb0350","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1016\/j.ymthe.2025.07.043","article-title":"ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells","volume":"33","author":"Liu","year":"2025","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0355","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-023-01768-0","article-title":"Epigenetic reprogramming of Runx3 reinforces CD8+T-cell function and improves the clinical response to immunotherapy","volume":"22","author":"Liu","year":"2023","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1070076","article-title":"Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis","volume":"14","author":"Lopes","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2026.02.003","article-title":"Persistent spatial immune responses in glioblastoma following oncolytic virus therapy","volume":"89","author":"Ma","year":"2026","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"7965","key":"10.1016\/j.pharmthera.2026.109124_bb0370","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41586-023-05968-y","article-title":"The neuroscience of cancer","volume":"618","author":"Mancusi","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0375","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0079-6123(02)37034-1","article-title":"Where the rubber meets the road: Netrin expression and function in developing and adult nervous systems","volume":"137","author":"Manitt","year":"2002","journal-title":"Progress in Brain Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109124_bb0380","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0385","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: From bedside to bench and back","volume":"39","author":"Mariniello","year":"2025","journal-title":"BioDrugs"},{"issue":"6371","key":"10.1016\/j.pharmthera.2026.109124_bb0390","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0395","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discovery"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109124_bb0400","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00432-022-04159-y","article-title":"Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors","volume":"149","author":"Mellgard","year":"2022","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109883","article-title":"\u03922-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME","volume":"37","author":"Mohammadpour","year":"2021","journal-title":"Cell Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0410","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2326-6066.CIR-17-0401","article-title":"\u0392-Adrenergic signaling impairs antitumor CD8+ T-cell responses to B-cell lymphoma immunotherapy","volume":"6","author":"Nissen","year":"2018","journal-title":"Cancer Immunology Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0420","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.cllc.2020.07.016","article-title":"The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"22","author":"Oh","year":"2021","journal-title":"Clinical Lung Cancer"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109124_bb0425","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/0008-5472.CAN-23-3628","article-title":"VPAC2 receptor signaling promotes pancreatic cancer cell growth and decreases the immunogenicity of the tumor microenvironment","volume":"84","author":"Passang","year":"2024","journal-title":"Cancer Research"},{"issue":"6316","key":"10.1016\/j.pharmthera.2026.109124_bb0430","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1288273","article-title":"Intravital imaging of the functions of immune cells in the tumor microenvironment during immunotherapy","volume":"14","author":"Peng","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.cels.2025.101261","article-title":"Combining spatial transcriptomics and ECM imaging in 3D for mapping cellular interactions in the tumor microenvironment","volume":"16","author":"Pentimalli","year":"2025","journal-title":"Cell Systems"},{"issue":"7655","key":"10.1016\/j.pharmthera.2026.109124_bb0445","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0450","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-025-02241-8","article-title":"Neuro-immune crosstalk in cancer: Mechanisms and therapeutic implications","volume":"10","author":"Pu","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0455","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0460","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/2326-6066.CIR-20-0445","article-title":"Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment","volume":"9","author":"Qiao","year":"2021","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0465","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1038\/s41467-022-34242-4","article-title":"Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Ravindranathan","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbi.2025.106076","article-title":"DCX+ cells cripple systemic spleen immunity and promote tumor progression","volume":"130","author":"Ren","year":"2025","journal-title":"Brain, Behavior, and Immunity"},{"issue":"35","key":"10.1016\/j.pharmthera.2026.109124_bb0475","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109124_bb0480","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"6371","key":"10.1016\/j.pharmthera.2026.109124_bb0485","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0490","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: Physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiological Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0495","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/ph18010075","article-title":"Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance","volume":"18","author":"Sabit","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109124_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0286651","article-title":"The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody","volume":"18","author":"Sakamoto","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0505","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10555-025-10241-x","article-title":"Sympathetic nerve signaling rewires the tumor microenvironment: A shift in \u201cmicroenvironmental-ity\u201d","volume":"44","author":"Sattler","year":"2025","journal-title":"Cancer Metastasis Reviews"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109124_bb0510","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1158\/1078-0432.CCR-21-4543","article-title":"Spatial and transcriptomic analysis of perineural invasion in oral cancer","volume":"28","author":"Schmitd","year":"2022","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0515","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10425179409039701","article-title":"High conservation of upstream regulatory sequences on the human and mouse vasoactive intestinal peptide (VIP) genes","volume":"5","author":"Sena","year":"1994","journal-title":"DNA Sequence: The Journal of DNA Sequencing and Mapping"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295684","article-title":"Unraveling the enigma of tumor-associated macrophages: Challenges, innovations, and the path to therapeutic breakthroughs","volume":"14","author":"Shao","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0525","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0530","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/0008-5472.CAN-18-3872","article-title":"Melanoma-induced reprogramming of schwann cell signaling aids tumor growth","volume":"79","author":"Shurin","year":"2019","journal-title":"Cancer Research"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109124_bb0535","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3390\/cells11223541","article-title":"Tumor-induced T cell polarization by schwann cells","volume":"11","author":"Shurin","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0540","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/icb.2015.62","article-title":"Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors","volume":"94","author":"Sreeramkumar","year":"2016","journal-title":"Immunology & Cell Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0545","article-title":"Impact of baseline medications on real-world overall survival in patients with cancer receiving immune checkpoint inhibitors in the RADIOHEAD cohort","volume":"7","author":"Stone","year":"2026","journal-title":"Medicine"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0550","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.oraloncology.2019.02.014","article-title":"Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade","volume":"91","author":"Tachinami","year":"2019","journal-title":"Oral Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2019.11.010","article-title":"Promising approaches in cancer immunotherapy","volume":"225","author":"Taefehshokr","year":"2020","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109124_bb0560","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2018.03.025","article-title":"T cell receptor-regulated TGF\u03b2 type I receptor expression determines T cell quiescence and activation","volume":"48","author":"Tu","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0565","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/2159-8290.CD-23-0397","article-title":"Nerves at play: The peripheral nervous system in extracranial malignancies","volume":"15","author":"Vermeer","year":"2025","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0570","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0575","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12943-023-01720-2","article-title":"Immunotherapies in rare cancers","volume":"22","author":"Vivekanandhan","year":"2023","journal-title":"Molecular Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0580","doi-asserted-by":"crossref","first-page":"899","DOI":"10.21037\/tcr-20-2738","article-title":"Combinatorial sympathetic and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockades inhibit the murine melanoma growth by targeting infiltrating T cells","volume":"10","author":"Wang","year":"2021","journal-title":"Translational Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2025.104982","article-title":"Revisiting TAM polarization: Beyond M1- and M2-type TAM toward clinical precision in macrophage-targeted therapy","volume":"143","author":"Wang","year":"2025","journal-title":"Experimental and Molecular Pathology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0590","article-title":"Artificial intelligence\u2013enabled multi-omics biomarkers for immune checkpoint blockade: Mechanisms, predictive modeling, and clinical translation","volume":"17","author":"Wang","year":"2026","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0595","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-025-00691-y","article-title":"Targeting collagen to optimize cancer immunotherapy","volume":"14","author":"Wang","year":"2025","journal-title":"Experimental Hematology & Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0600","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0605","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41698-024-00660-4","article-title":"Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census","volume":"8","author":"Wei","year":"2024","journal-title":"npj Precision Oncology"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0610","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12951-025-03924-8","article-title":"Reinvigorating CD8+ T cells through ADRB1 blockade using copper-propranolol nanoparticles for enhanced immune checkpoint blockade therapy","volume":"24","author":"Weng","year":"2026","journal-title":"Journal of Nanobiotechnology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109124_bb0615","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0620","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","article-title":"The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition","volume":"8","author":"Williams","year":"2024","journal-title":"npj Precision Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0625","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109124_bb0630","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013958","article-title":"Sensory neuron-derived CCL5 orchestrates an immunosuppressive niche via regulatory T cells to fuel head and neck tumor progression","volume":"14","author":"Wu","year":"2026","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1764513","article-title":"From escort to target, the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy","volume":"17","author":"Xiao","year":"2026","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109124_bb0640","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/biom16030400","article-title":"The neutrophil\u2013NET axis in immune checkpoint inhibitor resistance in non-small cell lung cancer: Roles, biomarkers and therapeutic opportunities","volume":"16","author":"Xu","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0645","article-title":"Perineural invasion and the \u201ccold\u201d tumor microenvironment in pancreatic cancer: Mechanisms of crosstalk and therapeutic opportunities","volume":"16","author":"Xu","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0650","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1038\/s41467-023-40314-w","article-title":"Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment","volume":"14","author":"Xue","year":"2023","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109124_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101621","article-title":"Advances and prospects of biomarkers for immune checkpoint inhibitors","volume":"5","author":"Yamaguchi","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109124_bb0660","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-19-2689","article-title":"Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109124_bb0665","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.ccell.2025.07.024","article-title":"Long-range cholinergic input promotes glioblastoma progression","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0670","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000495465","article-title":"Acute traumatic brain injury induces CD4+ and CD8+ T cell functional impairment by upregulating the expression of PD-1 via the activated sympathetic nervous system","volume":"26","author":"Yang","year":"2019","journal-title":"Neuroimmunomodulation"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109124_bb0675","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.3390\/cancers15245857","article-title":"Navigating the immune maze: Pioneering strategies for unshackling cancer immunotherapy resistance","volume":"15","author":"Yao","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0680","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41590-023-01723-7","article-title":"Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection","volume":"25","author":"Yin","year":"2024","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109124_bb0685","doi-asserted-by":"crossref","first-page":"510","DOI":"10.4049\/jimmunol.2101175","article-title":"LIGHT (TNFSF14) costimulation enhances myeloid cell activation and antitumor immunity in the setting of PD-1\/PD-L1 and TIGIT checkpoint blockade","volume":"209","author":"Yoo","year":"2022","journal-title":"The Journal of Immunology Author Choice"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116510","article-title":"Targeting tumor-associated sympathetic nerves orchestrates tertiary lymphoid structures to enhance PD-1\/PD-L1 blockade efficacy","volume":"177","author":"Zeng","year":"2026","journal-title":"International Immunopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109124_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101615","article-title":"Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE\/CTONG2104)","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109124_bb0700","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltaf012","article-title":"Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma","volume":"5","author":"Zhang","year":"2025","journal-title":"Immunotherapy Advances"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0705","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109124_bb0710","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011611","article-title":"ADRB2 inhibition suppresses cancer immune evasion by regulating tumor SOX10-PD-L1 axis and T cell function","volume":"13","author":"Zhang","year":"2025","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0715","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.bbi.2024.10.012","article-title":"Social isolation promotes tumor immune evasion via \u03b22-adrenergic receptor","volume":"123","author":"Zhao","year":"2025","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pharmthera.2026.109124_bb0720","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-024-03202-9","article-title":"Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer","volume":"43","author":"Zheng","year":"2024","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109124_bb0725","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jpainsymman.2021.09.009","article-title":"Acupuncture for quality of life in gastric cancer patients undergoing adjuvant chemotherapy","volume":"63","author":"Zhu","year":"2022","journal-title":"Journal of Pain and Symptom Management"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:33:31Z","timestamp":1791498811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":145,"alternative-id":["S0163725826001518"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109124","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroregulation as a modulatory force in immune checkpoint inhibitor resistance: mechanistic neuro-immune crosstalk informing biomarker-led diagnosis and targetable therapeutic sensitization","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109124"}}